natgillin/translations-raw huggingface dataset:
• Patients with severe aortic stenosis, patients with systolic blood pressure < 100 mm Hg, and patients with heart failure class NYHA III and NYHA IV. - Alert HCP about BRINAVESS special warnings and precautions in patients with, clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis, previously documented LVEF ≤ 35 %, advanced hepatic impairment. 
• Bolniki s hudo aortno stenozo, bolniki s sistoličnim krvnim tlakom < 100 mm Hg in bolniki s srčnim popuščanjem v razredu NYHA III ali NYHA IV. - Opozorilo za zdravstveno osebje glede posebnih opozoril in previdnostnih ukrepov za zdravilo BRINAVESS pri bolnikih s klinično pomembno stenozo zaklopk, hipertrofično obstruktivno kardiomiopatijo, restriktivno kardiomiopatijo ali konstriktivnim perikarditisom, predhodno dokumentiranim iztisnim deležem levega prekata (LVEF) ≤ 35 %, z napredovalo okvaro jeter.
Post-cardiac surgery patients: No dose adjustment necessary. 
Bolniki po kardiokirurški operaciji: Prilagoditev odmerka ni potrebna.
Vernakalant was not found to be effective in converting typical primary atrial flutter to sinus rhythm. 
Za vernakalant ni ugotovljeno, da bi učinkovito doseglo prehod tipične primarne atrijske undulacije v sinusni ritem.
There is limited experience with the use of vernakalant in patients with previously documented LVEF ≤ 35 %, its use in these patients is not recommended. 
Izkušenj z uporabo vernakalanta pri bolnikih s predhodno dokumentiranim iztisnim deležem levega prekata (LVEF) ≤ 35 % je malo, zato njegove uporabe pri takšnih bolnikih ne priporočamo.
BRINAVESS contains sodium 
Zdravilo BRINAVESS vsebuje natrij
• decreased feeling or sensitivity 
• zmanjšan občutek za občutljivost
The patient should be further monitored for 2 hrs after the start of infusion and until clinical and ECG parameters have stabilised. 
Bolnike je treba še naprej nadzorovati 2 uri po začetku infundiranja ter dokler se klinični in elektrokardiografski parametri ne stabilizirajo.
- Keep this leaflet. 
**Glejte spodaj.
This risk is higher in patients who use Class I antiarrhythmics (see section 4.8). 
Tveganje je večje pri bolnikih, ki prejemajo antiaritmike iz I. skupine (glejte poglavje 4.8).
ACT II examined the effect of vernakalant on patients who developed atrial fibrillation of < 3 days duration after recently undergoing coronary artery bypass graft, (CABG) and/or valvular surgery (atrial fibrillation occurred more than 1 day but less than 7 days after surgery). 
Študija ACT II je preučevala učinek vernakalanta pri bolnikih, ki se jim je pojavila < 3 dni trajajoča atrijska fibrilacija po nedavni obvodni koronarni operaciji (CABG) in/ali operaciji zaklopk (atrijska fibrilacija se je pojavila več kot 1 dan, a manj kot 7 dni po operaciji).
Patients with hepatic impairment: No dose adjustment necessary (see sections 4.4 and 5.2). 
Bolniki z okvaro jeter: Prilagoditev odmerka ni potrebna (glejte poglavji 4.4 in 5.2).
AVRO studied the effect of vernakalant versus intravenous amiodarone in patients with recent onset atrial fibrillation (3 hrs to 48 hrs). 
Študija AVRO je primerjala učinek vernakalanta in intravenskega amiodarona pri bolnikih s pred kratkim nastalo atrijsko fibrilacijo (od 3 ure do 48 ur).
Patients with renal impairment: No dose adjustment necessary (see section 5.2). 
Bolniki z okvaro ledvic: Prilagoditev odmerka ni potrebna (glejte poglavje 5.2).
Has the patient presented with an acute coronary syndrome (including myocardial infarction) in the last 30 days? 
Ali je bolnik imel akutni koronarni sindrom (vključno z miokardnim infarktom) v zadnjih 30 dneh?
• The other ingredients are citric acid, sodium chloride, sodium hydroxide (E524) and water for injections. 
• Pomožne snovi so citronska kislina, natrijev klorid, natrijev hidroksid (E524) in voda za injekcije.
It is not known whether BRINAVESS passes into the breast milk. 
Ni znano, ali zdravilo BRINAVESS prehaja v materino mleko.
• your blood pressure (such as a very low blood pressure causing a serious heart condition) 
• krvnega tlaka (kot zelo nizek krvni tlak, ki povzroči nevarno stanje srca) (občasni) • električnega delovanja srca (občasni)
Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults 
Hitra konverzija nedavno nastale atrijske fibrilacije v sinusni ritem pri odraslih
It should be taken into account that some people may get dizzy after receiving BRINAVESS, usually within the first 2 hours (see section “Possible side effects”). 
običajno se pojavi v prvih 2 urah (glejte poglavje "Možni neželeni učinki ").
The recommended initial dose is 3 mg/kg, with a maximum calculated dose based upon 113 kg. 
Priporočeni začetni odmerek je 3 mg/kg, z največjim izračunanim odmerkom za 113 kg.
If patients who received electrical cardioversion, intravenous antiarrhythmics or oral propafenone/flecainide within 90 minutes from the start of BRINAVESS infusion are regarded as treatment failures in addition to patients who did not convert for one minute within 90 minutes, the conversion rate among the 2,009 patients who received BRINAVESS was 67.3 % (1,352/2,009). 
Če štejemo za neuspeh zdravljenja bolnike, ki so prejeli električno kardioverzijo, intravenske antiaritmike ali peroralni propafenon/flekainid v 90 minutah od začetka infuzije zdravila BRINAVESS, poleg bolnikov, ki v 90 minutah niso pretvorili niti ene minute, je bila stopnja konverzije 67,3% (1.352/2.009) med 2.009 bolniki, ki so prejeli zdravilo BRINAVESS.
Targeted effects on atrial tissue coupled with block of late sodium current suggests that vernakalant has a low proarrhythmic potential. 
Usmerjeni učinki na tkivo preddvorov v povezavi z blokado poznega toka natrija kažejo, da je proaritmični potencial vernakalanta majhen.
Treatment with vernakalant effectively converted atrial fibrillation to sinus rhythm (47.0 % vernakalant, 14.0 % placebo; P value = 0.0001). 
Vernakalant je učinkovito dosegel prehod iz atrijske fibrilacije v sinusni ritem (vernakalant 47,0 %, placebo 14,0 %, vrednost p =
Dizziness has been reported within the first 2 hours after receiving it (see section 4.8). 
V prvih dveh urah po uporabi vernakalanta so poročali o omotici (glejte poglavje 4.8).
Step 3: Inspection of the solution 
3. korak: Raztopino preglejte
However, acute intravenous administration of vernakalant is not expected to markedly impact the PK of chronically administered 2D6 substrates, as a consequence of vernakalant's short half-life and the ensuing transient nature of 2D6 inhibition. 
Vendar ni pričakovati, da bi akutno intravensko dajanje vernakalanta izrazito vplivalo na farmakokinetiko kronično uporabljanih substratov 2D6, ker je razpolovni čas vernakalanta kratek in zato inhibicija 2D6 prehodna.
EXP Diluted solution: use within 12 hours and store at or below 25 °C. 
Razredčena raztopina: uporabite v 12 urah in shranjujte pri temperaturi do vključno 25 °C.
Some patients with typical atrial flutter were included in ACT II and ACT III and vernakalant was not found to be effective in converting atrial flutter. 
ACT III je bilo vključenih nekaj bolnikov z značilno atrijsko undulacijo in za vernakalanta ni bilo ugotovljeno, da bi učinkovito konvertiralo atrijsko undulacijo.
Furthermore, it has not been evaluated in patients with clinically meaningful valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy, or constrictive pericarditis and its use cannot be recommended in such cases. 
Poleg tega zdravilo ni bilo ovrednoteno pri bolnikih s klinično pomembno stenozo zaklopk, hipertrofično obstruktivno kardiomiopatijo, restriktivno kardiomiopatijo ali konstriktivnim perikarditisom.
• low blood pressure, slow heart beat, feeling dizzy 
• nizek krvni tlak, počasen srčni utrip, omotica
Each vial of 200 mg contains approximately 1.4 mmol (32 mg) sodium. 
Ena viala z 200 mg vsebuje približno 1,4 mmol (32 mg) natrija.
• Acute coronary syndrome (including myocardial infarction) within the last 30 days. 
• Akutni koronarni sindrom (vključno z miokardnim infarktom) v zadnjih 30 dneh.
Contains citric acid, sodium chloride, water for injections, sodium hydroxide (E524). 
SEZNAM POMOŽNIH SNOVI Vsebuje citronsko kislino, natrijev klorid, vodo za injekcije, natrijev hidroksid (E524).
Does the patient have severe bradycardia, sinus node dysfunction or second and third degree heart block, in the absence of a pacemaker? 
Ali ima bolnik hudo bradikardijo, disfunkcijo sinusnega vozla ali srčni blok 2. ali 3. stopnje brez srčnega spodbujevalnika?
• eye irritation, watery eyes or changes in your vision 
• draženje očesa, solzenje ali spremembe vida
BRINAVESS should be administered by intravenous infusion in a monitored clinical setting appropriate for cardioversion. 
Zdravilo BRINAVESS je treba dati v intravenski infuziji v nadzorovanem okolju, primernem za kardioverzijo.
Hypotension typically occurs early, either during the infusion or early after the end of the infusion, and can usually be corrected by standard supportive measures. 
Hipotenzija se praviloma pojavi zgodaj, bodisi med infundiranjem bodisi kmalu po koncu infundiranja.
Patients > 100 kg: 30 ml of BRINAVESS 20 mg/ml is added to 120 ml of diluent. 
Bolniki s telesno maso > 100 kg: 30 ml zdravila BRINAVESS 20 mg/ml dodajte 120 ml vehikla.
Within the clinical development program, oral maintenance antiarrhythmic therapy was halted for a minimum of 2 hours after vernakalant administration. 
V programu kliničnega razvoja so peroralno vzdrževalno zdravljenje z antiaritmiki prekinili za vsaj 2 uri po dajanju vernakalant.
• shortness of breath or a tightness in the chest 
• kratka sapa ali tiščanje v prsih
If conversion to sinus rhythm occurs during either the initial or second infusion, that infusion should be continued to completion. 
Če bolnik med začetno ali med drugo infuzijo preide v sinusni ritem, je treba infuzijo dokončati.
Vernakalant is an antiarrhythmic medicine that acts preferentially in the atria to prolong atrial refractoriness and to rate-dependently slow impulse conduction. 
Vernakalant je antiaritmično zdravilo, ki prednostno deluje v preddvorih, tako da podaljša njihovo refraktarnost in od frekvence odvisno upočasni prevajanje impulzov.
The amount of BRINAVESS you may be given will depend on your weight. 
Količina zdravila BRINAVESS, ki jo boste dobili, je odvisna od vaše telesne mase.
Each vial of 500 mg contains approximately 3.5 mmol (80 mg) of sodium. 
Ena viala s 500 mg vsebuje približno 3,5 mmol (80 mg) natrija.
What you need to know before you use BRINAVESS Do not use BRINAVESS 
Kaj morate vedeti, preden začnete uporabljati zdravilo BRINAVESS Ne uporabljajte zdravila BRINAVESS:
The checklist should be placed on the infusion container to be read by the healthcare professional who will administer BRINAVESS. 
Kontrolni seznam je treba namestiti na vsebnik infuzije z namenom, da ga prebere zdravstveni delavec, ki bo dal zdravilo BRINAVESS.
• numbness or tingling that occurs in the mucosa or tissues of the oral cavity 
• otrplost ali mravljinčenje, ki se pojavita v ustni sluznici ali ustnem tkivu
This medicine contains 80 mg of sodium (main component of cooking/table salt) in each vial of 500 mg. 
To zdravilo vsebuje 80 mg natrija (glavna sestavina kuhinjske/namizne soli) v eni viali s 500 mg.
Bradycardia was observed predominantly at the time of conversion to sinus rhythm. 
Bradikardijo so opažali predvsem v času prehoda v sinusni ritem.
Additionally, the ability of vernakalant to block the late component of the sodium current limits effects on ventricular repolarisation induced by blockade of potassium currents in the ventricle. 
Zmožnost vernakalanta za blokado pozne komponente natrijevega toka poleg tega omeji učinek na repolarizacijo prekatov, ki jo izzove blokada kalijevih tokov v prekatu.
If the patient was in atrial fibrillation or atrial flutter at the end of the 15-minute observation period, a second 10-minute infusion of 2.0 mg/kg BRINAVESS (or matching placebo) was administered. 
Če je imel bolnik na koncu 15-minutnega obdobja opazovanja atrijsko fibrilacijo ali atrijsko undulacijo, je bila uporabljena druga 10-minutna infuzija 2,0 mg/kg zdravila BRINAVESS (ali ujemajočega se placeba).
Posology BRINAVESS is dosed by patient body weight, with a maximum calculated dose based upon 113 kg. 
Zdravilo BRINAVESS se odmerja glede na bolnikovo telesno maso z največjim izračunanim odmerkom na podlagi mase 113 kg.
Preparation of BRINAVESS for infusion 
Priprava zdravila BRINAVESS za infundiranje
Although vernakalant is a substrate of CYP2D6, population pharmacokinetic (PK) analyses demonstrated that no substantial differences in the acute exposure of vernakalant (Cmax and AUC0-90min) were observed when weak or potent CYP2D6 inhibitors were administered within 1 day prior to vernakalant infusion compared to patients that were not on concomitant therapy with CYP2D6 inhibitors. 
Vernakalant je substrat za CYP2D6, toda populacijske farmakokinetične analize niso pokazale bistvene razlike v akutni izpostavljenosti vernakalantu (Cmax in AUC0-90min), če so bili v 1 dnevu pred infuzijo vernakalanta uporabljeni šibki ali močni zaviralci CYP2D6, kot če je bil vernakalant uporabljen pri bolnikih, ki sočasno niso prejemali zaviralcev CYP2D6.
There is limited experience with the use of intravenous rhythm control antiarrhythmics (class I and class III) in the first 4 hours after vernakalant administration, therefore these agents must not be used within this period (see section 4.3). 
Z uporabo intravenskih antiaritmikov za kontrolo srčnega ritma (skupini I in III) v prvih 4 urah po uporabi vernakalanta je malo izkušenj, zato se jih med tem obdobjem ne sme uporabljati (glejte poglavje 4.3).
BRINAVESS should not be administered as an intravenous push or bolus. 
Zdravila BRINAVESS se ne sme injicirati z intravenskim vbrizganjem oz. kot bolus.
Vernakalant has a minor to moderate influence on the ability to drive and use machines. 
4.7 Vpliv na sposobnost vožnje in upravljanja strojev Vernakalant ima blag do zmeren vpliv na sposobnost vožnje in upravljanje strojev.
Vernakalant was studied in 116 pts with atrial fibrillation (3 hrs to 48 hrs) including patients with hypertension (74.1 %), IHD (19 %), valvular heart disease (3.4 %) and CHF (17.2 %). 
Vernakalant so raziskali pri 116 bolnikih z atrijsko fibrilacijo (trajanje od 3 ure do 48 ur), med njimi so bili bolniki s hipertenzijo (74,1 %), ishemično boleznijo srca (19 %), boleznijo srčnih zaklopk (3,4 %) in kongestivnim srčnim popuščanjem (17,2 %).
Read carefully the Summary of Product Characteristics and the Health Care Professional Information Card prior to the administration of BRINAVESS 
Pred uporabo zdravila pozorno preberite Povzetek glavnih značilnosti zdravila in kartico z informacijami za zdravstvene delavce.
- Alert HCP about the need of precautions when using BRINAVESS in haemodynamically stable patients with congestive heart failure NYHA I and NYHA II and the need to monitor patients with valvular heart disease closely. 
- Opozorilo za zdravstveno osebje, da je pri uporabi zdravila BRINAVESS pri hemodinamsko stabilnih bolnikih s kongestivnim srčnim popuščanjem v razredih NYHA I in II potrebna previdnost ter da je treba bolnike z boleznijo srčnih zaklopk skrbno nadzorovati.
- Alert HCP on BRINAVESS contraindications: 
Opozorilo za zdravstveno osebje glede kontraindikacij za zdravilo BRINAVESS:
If conversion to sinus rhythm has not occurred, the patient's vital signs and cardiac rhythm should be observed for an additional 15 minutes. 
Če bolnik ne preide v sinusni ritem, morate še 15 minut spremljati njegove vitalne znake in srčni ritem.
As a precautionary measure, it is preferable to avoid the use of BRINAVESS during pregnancy. 
Iz previdnosti se je uporabi zdravila BRINAVESS med nosečnostjo bolje izogniti.
In patients with valvular heart disease, there was a higher incidence of ventricular arrhythmia events in vernakalant patients until 24 hours after dosing. 
Pri bolnikih z boleznijo srčnih zaklopk je bila pojavnost prekatnih motenj srčnega ritma večja pri tistih, ki so dobivali vernakalant do 24 ur po odmerjanju.
If atrial flutter is observed as secondary to treatment, continuation of infusion should be considered (see section 4.2). 
Če se sekundarno po uporabi zdravila pojavi atrijska undulacija, pride v poštev nadaljevanje infuzije (glejte poglavje 4.2).
• taste disturbances 
• motnje okušanja
BRINAVESS will be given to you by a health care professional. 
Zdravilo BRINAVESS vam bo dal zdravstveni delavec.
Within the first 2 hours, ventricular arrhythmia occurred in 6.4% of patients treated with vernakalant versus none after placebo. 
V prvih dveh urah se je pojavila ventrikularna aritmija pri 6,4% bolnikov, zdravljenih z vernakalantom, v primerjavi z nobenim po placebu.
Risk of atrial flutter may be increased in patients receiving class I AADs (see above). 
Tveganje za atrijsko undulacijo je lahko pri bolnikih, ki prejemajo antiaritmike skupine I, povečano (glejte zgoraj).
Uncommon: Pain in extremity 
Občasni: bolečina v okončini
There is no information on the excretion of vernakalant/metabolites in animal milk. 
Informacij o izločanju vernakalanta oz. njegovih presnovkov v mleko pri živalih ni.
This medicine contains 32 mg sodium (main component of cooking/table salt) in each 200 mg vial. 
To zdravilo vsebuje 32 mg natrija (glavna sestavina kuhinjske/namizne soli) v eni viali z 200 mg.
Treatment with vernakalant, converted 51.7 % of patients to SR at 90 minutes versus 5.2 % with amiodarone resulting in a significantly faster conversion rate from AF to SR within the first 90 minutes compared to amiodarone (log-rank P-value < 0.0001). 
Pri zdravljenju z vernakalantom je prehod v sinusni ritem v obdobju do 90 minut doseglo 51,7 % bolnikov, z amiodaronom pa 5,2 %, pri čemer je pri zdravljenju z vernakalantom značilno hitreje prišlo do prehoda iz atrijske fibrilacije v sinusni ritem v prvih 90 minutah kot pri zdravljenju z amiodaronom (vrednost p z log-rang testom < 0,0001).
Of the patients who did not convert to sinus rhythm, the incidence of bradycardia events in the first 2 hours post-dose was similar in placebo and vernakalant treated groups (4.0% and 3.8%, respectively). 
Med bolniki, ki niso prešli v sinusni ritem, je bila pojavnost dogodkov bradikardije v prvih 2 urah po odmerku v skupini s placebom podobna (4,0 %) kot v skupini z vernakalantom (3,8 %).
Efficacy in patients with sustained atrial fibrillation, (ACT I and ACT III) Primary efficacy endpoint was the proportion of subjects with short duration atrial fibrillation (3 hours to 7 days) who had a treatment-induced conversion of atrial fibrillation to sinus rhythm for a minimum duration of one minute within 90 minutes of first exposure to study drug. 
Učinkovitost pri bolnikih z obstojno atrijsko fibrilacijo (ACT I in ACT III) Primarni opazovani dogodek učinkovitosti je bil delež preiskovancev s kratkotrajno atrijsko fibrilacijo (od 3 ure do 7 dni), pri katerih je bil z zdravilom dosežen prehod iz atrijske fibrilacije v sinusni ritem za vsaj eno minuto in v 90 minutah od prve izpostavljenosti raziskovanemu zdravilu.
Your doctor will consider if you need additional rhythm control medicine 4 hours after using BRINAVESS. 
Zdravnik bo presodil, če 4 ure po uporabi zdravila BRINAVESS potrebujete dodatno zdravilo za urejanje srčnega ritma.
In clinical studies to date, patients who developed atrial flutter following treatment with vernakalant did not develop 1:1 atrioventricular conduction. 
V kliničnih študijah do danes se po zdravljenju z vernakalantom nobenemu bolniku, pri katerem se je pojavila atrijska undulacija, ni pojavilo atrioventrikularno prevajanje 1:1.
During this period, the patient should be carefully monitored for any signs or symptoms of a sudden decrease in blood pressure or heart rate. 
V tem obdobju je treba pri bolnikih skrbno spremljati ali se pojavijo kakršni koli znaki ali simptomi nenadnega znižanja krvnega tlaka ali srčnega utripa.
• The patient should be adequately hydrated and haemodynamically optimised and adequately anticoagulated (if necessary) prior to administering BRINAVESS 
• Pred dajanjem zdravila BRINAVESS morajo biti bolniki ustrezno hidrirani in hemodinamsko optimizirani ter (po potrebi) na ustreznem antikoagulantnem zdravljenju.
The recommended initial infusion is 3 mg/kg to be infused over a 10-minute period with a maximum initial dose of 339 mg (84.7 ml of 4 mg/ml solution). 
Priporočena začetna infuzija je 3 mg/kg in jo je treba dati v teku 10 minut z največjim začetnim odmerekom 339 mg (84,7 ml raztopine s koncentracijo 4 mg/ml).
Has the patient received an intravenous rhythm control antiarrhythmic drug (class I and/or class III) within 4 hours of the time when BRINAVESS will be infused? 
Ali je bolnik prejel intravenski antiaritmik za kontrolo srčnega ritma (skupine I in/ali III) v 4 urah pred načrtovano infuzijo zdravila BRINAVESS?
The initial infusion is administered as a 3 mg/kg dose over 10 minutes. 
Začetna infuzija je 3 mg/kg in jo je treba dati v teku 10 minut.
These anti-fibrillatory actions on refractoriness and conduction are thought to suppress re-entry, and are potentiated in the atria during atrial fibrillation. 
Domnevno ta antifibrilacijska učinka na refraktarnost in prevajanje zavreta kroženje in sta v preddvorih med atrijsko fibrilacijo izrazitejša.
In addition, acute exposure of vernakalant in poor metabolisers of CYP2D6 is only minimally different when compared to that of extensive metabolisers. 
Poleg tega je akutna izpostavljenost vernakalantu pri osebah s slabo funkcijo CYP2D6 le minimalno drugačna kot pri osebah z dobro funkcijo CYP2D6.
After dilution the concentration of the solution is 4 mg/ml vernakalant hydrochloride. 
Po redčenju je koncentracija raztopine 4 mg/ml vernakalantijevega klorida.
• The active substance is vernakalant hydrochloride. 
• Učinkovina je vernakalantijev klorid.
Vernakalant is a moderate, competitive inhibitor of CYP2D6. 
Vernakalant zmerno, kompetitivno zavira CYP2D6.
Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, single- and repeated-dose toxicity, and genotoxicity. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti enega in ponavljajočih se odmerkov in genotoksičnosti ne kažejo posebnega tveganja za človeka.
Do not re-start BRINAVESS. 
Zdravila ne smete dati ponovno.
Any vials exhibiting particulate matter or discolouration should not be used. 
Vial, ki vsebujejo delce ali imajo spremenjeno barvo vsebine, ne smete uporabiti.
• Patients with prolonged QT at baseline (uncorrected > 440 msec), or severe bradycardia, sinus node dysfunction or second degree and third degree heart block in the absence of a pacemaker. 
• Bolniki z izhodiščnim podaljšanjem QT (nekorigirani QT > 440 ms) ali s hudo bradikardijo, disfunkcijo sinusnega vozla ali srčnim blokom 2. ali 3. stopnje brez srčnega spodbujevalnika.
As the clinical trial experience in patients with advanced hepatic impairment is limited, vernakalant is not recommended in these patients. 
Izkušenj pri bolnikih z napredovalo okvaro jeter iz kliničnih preskušanj je malo, zato vernakalanta pri takšnih bolnikih ne priporočamo.
Create a solution with a concentration of 4 mg/ml following the dilution guidelines below: Patients ≤ 100 kg: 25 ml of BRINAVESS 20 mg/ml is added to 100 ml of diluent. 
Pripravite raztopino s koncentracijo 4 mg/ml z upoštevanjem naslednjih navodil za razredčenje: Bolniki s telesno maso ≤ 100 kg: 25 ml zdravila BRINAVESS 20 mg/ml dodajte 100 ml vehikla.
-For non-surgery patients: atrial fibrillation ≤ 7 days duration 
- za nekirurške bolnike: atrijska fibrilacija, ki traja ≤ 7 dni.
What BRINAVESS looks like and contents of the pack 
Izgled zdravila BRINAVESS in vsebina pakiranja
The diluted sterile solution should be clear, colourless to pale yellow. 
Razredčena sterilna raztopina mora biti bistra in brezbarvna do bledorumena.
Common: Hypotension Uncommon: Flushing; hot flush; pallor 
Pogosti: hipotenzija Občasni: zardevanje, vročinski oblivi, bledica
Patients receiving vernakalant have a higher incidence of converting to atrial flutter within the first 2 hours post-dose. 
Med bolniki, ki prejmejo vernakalant, je večja pojavnost prehoda v atrijsko undulacijo v prvih 2 urah po odmerku.